Detalhe da pesquisa
1.
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.
Blood
; 123(12): 1833-5, 2014 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-24443442
2.
Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies.
Cancer Med
; 12(9): 10612-10624, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37021939
3.
The European LeukemiaNet: achievements and perspectives.
Haematologica
; 96(1): 156-62, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21048032
4.
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib.
Leukemia
; 35(2): 485-493, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33414483
5.
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19.
Blood Cancer J
; 11(2): 21, 2021 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33563901
6.
Long-term follow-up of recovered MPN patients with COVID-19.
Blood Cancer J
; 11(6): 115, 2021 06 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34135309